NMR systems and methods for the rapid detection of analytes
This invention features systems and methods for the detection of analytes, and their use in the treatment and diagnosis of disease.
1. A method of monitoring one or more nucleic acid analytes in a whole blood sample derived from a patient for the diagnosis, management, or treatment of a medical condition in the patient, wherein the one or more nucleic acid analytes have been amplified in the whole blood sample, the method comprising:
(a) combining with the sample from 1×10 6 to 1×10 13 magnetic particles per milliliter of the sample, wherein the magnetic particles have a mean diameter of from 700 nm to 950 nm and a T 2 relaxivity per particle of from 1×10 9 to 1×10 12 mM −1 s −1 , and wherein the magnetic particles have binding moieties on their surfaces, the binding moieties operative to alter the specific aggregation of the magnetic particles in the presence of the one or more nucleic acid analytes or a multivalent binding agent;
(b) placing the sample in a device, the device comprising a support defining a well for holding the sample comprising the magnetic particles and the one or more nucleic acid analytes, and having an RF coil disposed about the well, the RF coil configured to detect a signal produced by exposing the sample to a bias magnetic field created using one or more magnets and an RF pulse sequence;
(c) exposing the sample to a bias magnetic field and an RF pulse sequence;
(d) following step (c), measuring the signal, thereby monitoring the one or more nucleic acid analytes; and
(e) using the result of step (d) to diagnose, manage, or treat the medical condition.
2. The method of claim 1 , wherein the patient is immunocompromised and the one or more nucleic acid analytes comprise a pathogen-associated analyte.
3. The method of claim 1 , wherein the one or more nucleic acid analytes comprise Candida spp. nucleic acid.
4. The method of claim 1 , wherein the patient has cancer, and the one or more nucleic acid analytes are genetic markers present in a cancer cell.
5. The method of claim 1 , wherein the patient has, or is at risk of, an infection, and the one or more nucleic acid analytes comprise a pathogen-associated analyte.
6. The method of claim 5 , wherein the infection is an opportunistic infection.
7. The method of claim 5 , wherein the infection is a fungal infection, a gram-negative bacterial infection, or a gram-positive bacterial infection.
8. The method of claim 7 , wherein the fungal infection is a Candida infection.
9. The method of claim 8 , wherein the Candida infection is an infection by a Candida species selected from the group consisting of C. albicans, C. glabrata, C. krusei, C. tropicalis , and C. parapsilosis.
10. The method of claim 7 , wherein the gram-negative bacterial infection is an infection by a gram negative bacterium selected from the group consisting of Escherichia coli, Stenotrophomonas maltophilia, Klebsiella pneumoniae, Klebsiella oxytoca , and Pseudomonas aeruginosa.
11. The method of claim 7 , wherein the gram-positive bacterial infection is an infection by a gram-positive bacterium selected from the group consisting of Staphylococcus aureus, Staphylococcus pneumoniae, Enterococcus faecalis , and Enterococcus faecium.
12. The method of claim 1 , wherein the monitoring is intermittent.
13. The method of claim 1 , wherein the monitoring is continuous.
14. The method of claim 1 , the medical condition is selected from the group consisting of bacteremia, Candidemia, sepsis, and Systemic Inflammatory Response syndrome (SIRS).
15. The method of claim 1 , further comprising using the results of the method to select a therapeutic intervention.